Literature DB >> 30046901

Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease.

Giovanna Stefania Colafati1, Enrica Rossi2, Chiara Carducci3, Simone Piga4, Ioan Paul Voicu5, Angela Mastronuzzi5, Paolo Tomà2.   

Abstract

BACKGROUND: Given the recent concerns about gadolinium-based contrast agent safety, dose reduction strategies are being investigated.
OBJECTIVE: To compare half-dose and standard full-dose gadoterate meglumine at 3-tesla (T) MRI in paediatric bone and soft-tissue diseases.
MATERIALS AND METHODS: We prospectively enrolled 45 children (age range 2.7 months to 17.5 years, median age 8.7 years, 49 total anatomical segments) with bone and soft-tissue diseases (neoplastic, inflammatory/infectious, ischaemic and vascular) imaged at 3-T MRI. Two consecutive half-doses of gadoterate meglumine (0.05 mmol/kg body weight) were administered. Two sets of post-contrast T1-weighted images were obtained, one after the first half dose and the other after the second half dose. For qualitative analysis, three radiologists, masked to the gadolinium dose, compared the diagnostic quality of the images. For quantitative analysis, we compared signal-to-noise ratio and contrast-to-noise ratio at half and full doses.
RESULTS: Signal-to-noise ratio and contrast-to-noise ratio did not vary significantly between the two groups. Qualitative analysis yielded excellent image quality in both post-contrast image datasets (Cohen κ=0.8).
CONCLUSION: In paediatric bone and soft-tissue 3-T MRI, it is feasible to halve the standard dose of gadoterate meglumine without losing image quality.

Entities:  

Keywords:  3-T; Children; Contrast agent; Contrast-to-noise ratio; Dose; Gadolinium; Gadoterate meglumine; Magnetic resonance imaging; Signal-to-noise ratio

Mesh:

Substances:

Year:  2018        PMID: 30046901     DOI: 10.1007/s00247-018-4204-y

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  37 in total

1.  Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors.

Authors:  Colleen M Costelloe; William A Murphy; Tamara M Haygood; Rajendra Kumar; Kevin W McEnery; R Jason Stafford; Anjali Roy; Roland L Bassett; Robyn K Harrell; John E Madewell
Journal:  Skeletal Radiol       Date:  2010-09-24       Impact factor: 2.199

2.  Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model.

Authors:  Sohi Bae; Ho-Joon Lee; Kyunghwa Han; Yae-Won Park; Yoon Seong Choi; Sung Soo Ahn; Jinna Kim; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2017-01-12       Impact factor: 5.315

3.  Enhancement in a brain glioma model: a comparison of half-dose gadobenate dimeglumine versus full-dose gadopentetate dimeglumine at 1.5 and 3 T.

Authors:  John N Morelli; Clint M Gerdes; Wei Zhang; Jonathon M Williams; Megan R Saettele; Fei Ai
Journal:  J Magn Reson Imaging       Date:  2013-06-04       Impact factor: 4.813

4.  Contrast enhanced renal MR angiography at 7 Tesla: How much gadolinium do we need?

Authors:  Karsten Beiderwellen; Oliver Kraff; Anja Laader; Stefan Maderwald; Stephan Orzada; Mark E Ladd; Michael Forsting; Thomas C Lauenstein; Lale Umutlu
Journal:  Eur J Radiol       Date:  2016-11-05       Impact factor: 3.528

5.  Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.

Authors:  Beatrice Nardone; Elise Saddleton; Anne E Laumann; Beatrice J Edwards; Dennis W Raisch; June M McKoy; Steven M Belknap; Christian Bull; Anand Haryani; Shawn E Cowper; Ali K Abu-Alfa; Frank H Miller; Victoria Godinez-Puig; Vikas R Dharnidharka; Dennis P West
Journal:  Pediatr Radiol       Date:  2013-09-21

6.  Pediatric Brain: No Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-weighted MR Images after Consecutive Exposure to a Macrocyclic Gadolinium-based Contrast Agent.

Authors:  Alexander Radbruch; Robert Haase; Philipp Kickingereder; Philipp Bäumer; Sebastian Bickelhaupt; Daniel Paech; Wolfgang Wick; Heinz-Peter Schlemmer; Angelika Seitz; Martin Bendszus
Journal:  Radiology       Date:  2017-03-08       Impact factor: 11.105

Review 7.  Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.

Authors:  Val M Runge
Journal:  Invest Radiol       Date:  2017-06       Impact factor: 6.016

8.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

9.  Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities.

Authors:  Robert J McDonald; Jennifer S McDonald; David F Kallmes; Mark E Jentoft; Michael A Paolini; David L Murray; Eric E Williamson; Laurence J Eckel
Journal:  Radiology       Date:  2017-06-27       Impact factor: 11.105

10.  Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.

Authors:  Philippe Soyer; Anthony Dohan; Deepak Patkar; Andreas Gottschalk
Journal:  J Magn Reson Imaging       Date:  2016-10-11       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.